Jacobson Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Derek Sum
Chief executive officer
HK$13.7m
Total compensation
| CEO salary percentage | 25.4% |
| CEO tenure | 8.3yrs |
| CEO ownership | 59.4% |
| Management average tenure | no data |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | HK$245m |
| Jun 30 2023 | n/a | n/a | HK$248m |
| Mar 31 2023 | HK$14m | HK$3m | HK$251m |
| Dec 31 2022 | n/a | n/a | HK$207m |
| Sep 30 2022 | n/a | n/a | HK$203m |
| Jun 30 2022 | n/a | n/a | HK$190m |
| Mar 31 2022 | HK$5m | HK$3m | HK$178m |
| Dec 31 2021 | n/a | n/a | HK$166m |
| Sep 30 2021 | n/a | n/a | HK$154m |
| Jun 30 2021 | n/a | n/a | HK$164m |
| Mar 31 2021 | HK$5m | HK$4m | HK$174m |
| Dec 31 2020 | n/a | n/a | HK$183m |
| Sep 30 2020 | n/a | n/a | HK$191m |
| Jun 30 2020 | n/a | n/a | HK$203m |
| Mar 31 2020 | HK$5m | HK$4m | HK$214m |
| Sep 30 2019 | n/a | n/a | HK$273m |
| Jun 30 2019 | n/a | n/a | HK$259m |
| Mar 31 2019 | HK$5m | HK$4m | HK$245m |
| Dec 31 2018 | n/a | n/a | HK$235m |
| Sep 30 2018 | n/a | n/a | HK$219m |
| Jun 30 2018 | n/a | n/a | HK$211m |
| Mar 31 2018 | HK$6m | HK$4m | HK$202m |
Compensation vs Market: Derek's total compensation ($USD1.75M) is above average for companies of similar size in the Hong Kong market ($USD233.89K).
Compensation vs Earnings: Derek's compensation has increased by more than 20% in the past year.
CEO
Derek Sum (60 yo)
8.3yrs
Tenure
HK$13,692,000
Compensation
Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.3yrs | HK$13.69m | 59.42% HK$ 677.5m | |
| VP of Administration & Executive Director | 7.3yrs | HK$4.53m | 0.39% HK$ 4.5m | |
| Executive Director | 8.1yrs | HK$8.03m | 1.97% HK$ 22.5m | |
| Independent Non-Executive Director | 8.1yrs | HK$226.00k | no data | |
| Independent Non-Executive Director | 7.8yrs | HK$226.00k | no data | |
| Member of Scientific Advisory Committee | 8.1yrs | no data | no data | |
| Member of Scientific Advisory Committee | 8.1yrs | no data | no data | |
| Member of Scientific Advisory Committee | 8.1yrs | no data | no data | |
| Non-Executive Director & Member of Scientific Advisory Committee | 8.1yrs | HK$226.00k | no data | |
| Independent Non-Executive Director | 7.8yrs | HK$226.00k | 0.030% HK$ 342.0k |
8.1yrs
Average Tenure
60yo
Average Age
Experienced Board: 2633's board of directors are considered experienced (8.1 years average tenure).